Cargando…
Apoptosis-based therapy to treat pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is rare, but patients who are diagnosed with this disease still suffer from a lack of satisfactory treatment strategies to prolong survival. While currently approved drugs for PAH have some benefits, these vasodilators only have limited efficacy for eliminating...
Autores principales: | Suzuki, Yuichiro J., Ibrahim, Yasmine F., Shults, Nataliia V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094193/ https://www.ncbi.nlm.nih.gov/pubmed/27819072 |
Ejemplares similares
-
COVID-19 patients may become predisposed to pulmonary arterial hypertension
por: Suzuki, Yuichiro J., et al.
Publicado: (2021) -
Ultrastructural Changes of the Right Ventricular Myocytes in Pulmonary Arterial Hypertension
por: Shults, Nataliia V., et al.
Publicado: (2019) -
Oxidative profiling of the failing right heart in rats with pulmonary hypertension
por: Wang, Xinhong, et al.
Publicado: (2017) -
Effects of Bcl-2/Bcl-x(L) Inhibitors on Pulmonary Artery Smooth Muscle Cells
por: Rybka, Vladyslava, et al.
Publicado: (2018) -
Case Report: Two Case Reports of Pulmonary Hypertension after mRNA COVID-19 Vaccination
por: Sullivan, Robert D., et al.
Publicado: (2023)